{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:40:57Z","timestamp":1792442457703,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"DOI":"10.1007\/s40121-026-01464-8","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:03:05Z","timestamp":1792396985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Simplifying Adult Pneumococcal Vaccination in India: A Cost-Effectiveness Analysis of the 20-Valent Conjugate Vaccine"],"prefix":"10.1007","author":[{"given":"Santosh","family":"Taur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Choudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Averin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Suokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"MacKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Atwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-7698","authenticated-orcid":false,"given":"Liping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"3","key":"1464_CR1","first-page":"216","volume":"36","author":"PA Koul","year":"2019","unstructured":"Koul PA, Chaudhari S, Chokhani R, Christopher D, Dhar R, Doshi K, et\u00a0al. Pneumococcal disease burden from an Indian perspective: need for its prevention in pulmonology practice. Lung India. 2019;36(3):216\u201325.","journal-title":"Lung India"},{"issue":"6","key":"1464_CR2","volume":"16","author":"VB Vikhe","year":"2024","unstructured":"Vikhe VB, Faruqi AA, Patil RS, Patel H, Khandol D, Reddy A. A study on the etiology and clinical manifestations of community-acquired pneumonia in adults in Western India. Cureus. 2024;16(6):e63132.","journal-title":"Cureus"},{"issue":"7","key":"1464_CR3","volume":"16","author":"VB Vikhe","year":"2024","unstructured":"Vikhe VB, Faruqi AA, Patil RS, Reddy A, Khandol D. A systematic review of community-acquired pneumonia in Indian adults. Cureus. 2024;16(7):e63976.","journal-title":"Cureus"},{"issue":"1","key":"1464_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2012.04.006","volume":"66","author":"K Thomas","year":"2013","unstructured":"Thomas K, Mukkai Kesavan L, Veeraraghavan B, Jasmine S, Jude J, Shubankar M, et\u00a0al. Invasive pneumococcal disease associated with high case fatality in India. J Clin Epidemiol. 2013;66(1):36\u201343.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"1464_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jmii.2018.03.004","volume":"52","author":"R Jayaraman","year":"2019","unstructured":"Jayaraman R, Varghese R, Kumar JL, Neeravi A, Shanmugasundaram D, Ralph R, et\u00a0al. Invasive pneumococcal disease in Indian adults: 11 years\u2019 experience. J Microbiol Immunol Infect. 2019;52(5):736\u201342.","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"1464_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2471\/BLT.21.287390","volume":"100","author":"AA Rizvi","year":"2022","unstructured":"Rizvi AA, Singh A. Vaccination coverage among older adults: a population-based study in India. Bull World Health Organ. 2022;100(6):375\u201384.","journal-title":"Bull World Health Organ"},{"key":"1464_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10122124","author":"D Singh","year":"2022","unstructured":"Singh D, Sinha A, Kanungo S, Pati S. Disparities in coverage of adult immunization among older adults in India. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10122124.","journal-title":"Vaccines"},{"key":"1464_CR8","unstructured":"Ghosh S. The Health Care System in India. CRC 1342 Social Policy Country Briefs; Series Volume: 49. 2025."},{"issue":"12","key":"1464_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050077","volume":"11","author":"B Reshmi","year":"2021","unstructured":"Reshmi B, Unnikrishnan B, Rajwar E, Parsekar SS, Vijayamma R, Venkatesh BT. Impact of public-funded health insurances in India on health care utilisation and financial risk protection: a systematic review. BMJ Open. 2021;11(12):e050077.","journal-title":"BMJ Open"},{"key":"1464_CR10","unstructured":"Vora A, Tiwaskar M, Lele J. Indian consensus guideline on adult immunization 2026 update. 2026. https:\/\/www.linkedin.com\/posts\/dr-rajiv-kumar-jain-568a0910_consensus-guidelines-on-adult-immunization-ugcPost-7442887640443703296-8oWa\/. Accessed July 23 2026."},{"issue":"3","key":"1464_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4161\/hv.23268","volume":"9","author":"S Boccalini","year":"2013","unstructured":"Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother. 2013;9(3):699\u2013706.","journal-title":"Hum Vaccin Immunother"},{"issue":"50","key":"1464_CR12","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1016\/j.vaccine.2013.10.024","volume":"31","author":"B-H Cho","year":"2013","unstructured":"Cho B-H, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011\u201321.","journal-title":"Vaccine"},{"issue":"8","key":"1464_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10096-007-0327-z","volume":"26","author":"SMAA Evers","year":"2007","unstructured":"Evers SMAA, Ament AJHA, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, et\u00a0al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis. 2007;26(8):531\u201340.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"1464_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0264-410X(02)00451-6","volume":"21","author":"AM Fry","year":"2002","unstructured":"Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. 2002;21(3):303\u201311.","journal-title":"Vaccine"},{"issue":"5","key":"1464_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177342","volume":"12","author":"JY Heo","year":"2017","unstructured":"Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, et\u00a0al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS ONE. 2017;12(5):e0177342.","journal-title":"PLoS ONE"},{"issue":"10","key":"1464_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139140","volume":"10","author":"S-l Hoshi","year":"2015","unstructured":"Hoshi S-l, Kondo M, Okubo I. Economic evaluation of immunisation programme of 23-valent pneumococcal polysaccharide vaccine and the inclusion of 13-valent pneumococcal conjugate vaccine in the list for single-dose subsidy to the elderly in Japan. PLoS ONE. 2015;10(10):e0139140.","journal-title":"PLoS ONE"},{"issue":"18","key":"1464_CR17","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1001\/archinte.167.18.1938","volume":"167","author":"J Johnstone","year":"2007","unstructured":"Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007;167(18):1938\u201343.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1464_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/2191-1991-2-4","volume":"2","author":"A Kuhlmann","year":"2012","unstructured":"Kuhlmann A, Theidel U, Pletz MW, von der Schulenburg JMG. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev. 2012;2(1):4.","journal-title":"Health Econ Rev"},{"key":"1464_CR19","doi-asserted-by":"crossref","unstructured":"Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database System Rev. 2013(1).","DOI":"10.1002\/14651858.CD000422.pub3"},{"issue":"9100","key":"1464_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0140-6736(97)07358-3","volume":"351","author":"\u00c5 \u00d6rtqvist","year":"1998","unstructured":"\u00d6rtqvist \u00c5, Hedlund J, Burman L-\u00c5, Elbel E, H\u00f6fer M, Leinonen M, et\u00a0al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet. 1998;351(9100):399\u2013403.","journal-title":"Lancet"},{"issue":"21","key":"1464_CR21","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJM198611203152104","volume":"315","author":"MS Simberkoff","year":"1986","unstructured":"Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, et\u00a0al. Efficacy of pneumococcal vaccine in high-risk patients. N Engl J Med. 1986;315(21):1318\u201327.","journal-title":"N Engl J Med"},{"issue":"4","key":"1464_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amepre.2012.11.035","volume":"44","author":"KJ Smith","year":"2013","unstructured":"Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prevent Med. 2013;44(4):373\u201381.","journal-title":"Am J Prevent Med."},{"issue":"8","key":"1464_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s11606-016-3651-0","volume":"31","author":"C Stoecker","year":"2016","unstructured":"Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31(8):901\u20138.","journal-title":"J Gen Intern Med"},{"issue":"7","key":"1464_CR24","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.vaccine.2019.12.029","volume":"38","author":"C Stoecker","year":"2020","unstructured":"Stoecker C, Kobayashi M, Matanock A, Cho B-H, Pilishvili T. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020;38(7):1770\u20137.","journal-title":"Vaccine"},{"issue":"1","key":"1464_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29280-2","volume":"8","author":"H Latifi-Navid","year":"2018","unstructured":"Latifi-Navid H, Latifi-Navid S, Mostafaiy B, Jamalkandi SA, Ahmadi A. Pneumococcal disease and the effectiveness of the PPV23 vaccine in adults: a two-stage Bayesian meta-analysis of observational and RCT reports. Sci Rep. 2018;8(1):11051.","journal-title":"Sci Rep"},{"issue":"5","key":"1464_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177985","volume":"12","author":"M Tin Tin Htar","year":"2017","unstructured":"Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, et\u00a0al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS ONE. 2017;12(5):e0177985.","journal-title":"PLoS ONE"},{"issue":"12","key":"1464_CR27","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","volume":"372","author":"MJM Bonten","year":"2015","unstructured":"Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et\u00a0al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114\u201325.","journal-title":"N Engl J Med"},{"key":"1464_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2026.100780","volume":"28","author":"DV Pachito","year":"2026","unstructured":"Pachito DV, Almeida PHRF, Ferreira RM, Alexandre RF, Burian APN. Real-world estimation of the pneumococcal vaccination coverage among high-risk population in the unified health system in Brazil: an administrative database analysis. Vaccine X. 2026;28:100780.","journal-title":"Vaccine X"},{"key":"1464_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13080807","author":"A Bongiovanni","year":"2025","unstructured":"Bongiovanni A, Santolini G, Vairo F, Corea F, Aquilani S, de Waure C. Analysis of sequential pneumococcal vaccination coverage in the elderly resident population of the Viterbo Local Health Authority from 2018 to 2023. Vaccines.\u00a02025 Jul 30;13(8):807.","journal-title":"Vaccines"},{"key":"1464_CR30","unstructured":"Scanx. Pfizer Introduces Advanced 20-Valent Pneumococcal Vaccine for Adults in India. 2025. https:\/\/scanx.trade\/stock-market-news\/global\/pfizer-introduces-advanced-20-valent-pneumococcal-vaccine-for-adults-in-india\/16473156. Accessed February 13 2026."},{"issue":"6","key":"1464_CR31","first-page":"580","volume":"105","author":"AA Shah","year":"2022","unstructured":"Shah AA. Simplifying pneumococcal immunizations for adults. Am Fam Physician. 2022;105(6):580\u20131.","journal-title":"Am Fam Physician"},{"issue":"9","key":"1464_CR32","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/infdis\/jis212","volume":"205","author":"EA Clutterbuck","year":"2012","unstructured":"Clutterbuck EA, Lazarus R, Yu L-M, Bowman J, Bateman EAL, Diggle L, et\u00a0al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408\u201316.","journal-title":"J Infect Dis"},{"key":"1464_CR33","doi-asserted-by":"crossref","unstructured":"Kulkarni N, Averin A, Taur S, Huang L, Hariharan D, Atwood M, et al. Cost-effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine in Indian adults aged \u226550 years. Expert Rev Pharmacoecon Outcomes Res. 2025;25(7):1087\u201399.","DOI":"10.1080\/14737167.2025.2508255"},{"issue":"8","key":"1464_CR34","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","volume":"22","author":"D Mendes","year":"2022","unstructured":"Mendes D, Averin A, Atwood M, Sato R, Vyse A, Campling J, et\u00a0al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022;22(8):1285\u201395.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"1464_CR35","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14760584.2023.2262575","volume":"22","author":"F Kuhne","year":"2023","unstructured":"Kuhne F, Achtert K, Puschner F, Urbanski-Rini D, Schiller J, Mahar E, et\u00a0al. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany. Expert Rev Vaccines. 2023;22(1):921\u201332.","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"1464_CR36","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40121-024-00972-9","volume":"13","author":"L Rey-Ares","year":"2024","unstructured":"Rey-Ares L, Averin A, Mac Mullen M, Hariharan D, Atwood M, Carballo C, et\u00a0al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Argentinean adults. Infect Dis Ther. 2024;13(6):1235\u201351.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1464_CR37","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1080\/14760584.2023.2273892","volume":"22","author":"S Marbaix","year":"2023","unstructured":"Marbaix S, Mignon A, Taelman A, Averin A, Atwood M, Vietri J. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults. Expert Rev Vaccines. 2023;22(1):1008\u201321.","journal-title":"Expert Rev Vaccines"},{"key":"1464_CR38","unstructured":"Pfizer India Ltd. Data on File."},{"issue":"5","key":"1464_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.focus.2025.100384","volume":"4","author":"A Averin","year":"2025","unstructured":"Averin A, Vietri J, Mohs AA, Willis SJ, Lonshteyn A, Weycker D. Uptake of pneumococcal vaccines among U.S. adults after 2022 update to recommendations. AJPM Focus. 2025;4(5):100384.","journal-title":"AJPM Focus"},{"key":"1464_CR40","unstructured":"Worldometer. Worldometer India Population (LIVE). 28th May 2025. 2025. https:\/\/www.worldometers.info\/world-population\/india-population\/. Accessed May 28 2025."},{"key":"1464_CR41","unstructured":"United Nations. UN World Population Prospects 2024 release, 2023 data. 2024. https:\/\/population.un.org\/wpp\/. Accessed May 28 2025."},{"key":"1464_CR42","unstructured":"Centers for Disease Control and Prevention. Pneumococcal Disease: Risk Factors 2023. https:\/\/www.cdc.gov\/pneumococcal\/clinicians\/risk-factors.html. Accessed February 1, 2024 2024."},{"issue":"11","key":"1464_CR43","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/cid\/ciy800","volume":"68","author":"SI Pelton","year":"2019","unstructured":"Pelton SI, Bornheimer R, Doroff R, Shea KM, Sato R, Weycker D. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019;68(11):1831\u20138.","journal-title":"Clin Infect Dis"},{"key":"1464_CR44","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 2011 2011. https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu11.pdf. Accessed April 17 2023."},{"issue":"38","key":"1464_CR45","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1016\/j.vaccine.2008.07.016","volume":"26","author":"JC Nelson","year":"2008","unstructured":"Nelson JC, Jackson M, Yu O, Whitney CG, Bounds L, Bittner R, et\u00a0al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26(38):4947\u201354.","journal-title":"Vaccine"},{"key":"1464_CR46","unstructured":"National Health Interview Survey. 2018."},{"key":"1464_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106476","author":"A Averin","year":"2021","unstructured":"Averin A, Shaff M, Weycker D, Lonshteyn A, Sato R, Pelton SI. Mortality and readmission in the year following hospitalization for pneumonia among US adults. Respir Med. 2021. https:\/\/doi.org\/10.1016\/j.rmed.2021.106476.","journal-title":"Respir Med"},{"key":"1464_CR48","unstructured":"Office of the Registrar General & Census Commissioner. Sample Registration System (SRS) - Abridged Life Tables 2016\u20132020. Ministry of Home Affairs, Government of India; 2022."},{"issue":"5","key":"1464_CR49","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","volume":"46","author":"MJ Mangen","year":"2015","unstructured":"Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, et\u00a0al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407\u201316.","journal-title":"Eur Respir J"},{"key":"1464_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","volume":"6","author":"A Djennad","year":"2018","unstructured":"Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, et\u00a0al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42\u201350.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1464_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jinf.2012.02.017","volume":"65","author":"AJ van Hoek","year":"2012","unstructured":"van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et\u00a0al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17\u201324.","journal-title":"J Infect"},{"issue":"5-6","key":"1464_CR52","doi-asserted-by":"publisher","first-page":"756","DOI":"10.17269\/s41997-018-0050-9","volume":"109","author":"M Atwood","year":"2018","unstructured":"Atwood M, Beausoleil L, Breton MC, Laferriere C, Sato R, Weycker D. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults. Can J Public Health. 2018;109(5\u20136):756\u201368.","journal-title":"Can J Public Health"},{"issue":"7","key":"1464_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199427","volume":"13","author":"S Marbaix","year":"2018","unstructured":"Marbaix S, Peetermans WE, Verhaegen J, Annemans L, Sato R, Mignon A, et\u00a0al. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. PLoS ONE. 2018;13(7):e0199427.","journal-title":"PLoS ONE"},{"issue":"36","key":"1464_CR54","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1016\/j.vaccine.2012.05.076","volume":"30","author":"D Weycker","year":"2012","unstructured":"Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged >\/=50 years. Vaccine. 2012;30(36):5437\u201344.","journal-title":"Vaccine"},{"issue":"3","key":"1464_CR55","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/cid\/ciab990","volume":"75","author":"B Essink","year":"2022","unstructured":"Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et\u00a0al. Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults Aged >\/=18 Years. Clin Infect Dis. 2022;75(3):390\u20138.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1464_CR56","doi-asserted-by":"publisher","first-page":"960","DOI":"10.7326\/0003-4819-138-12-200306170-00007","volume":"138","author":"JE Sisk","year":"2003","unstructured":"Sisk JE, Whang W, Butler JC, Sneller V-P, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960\u20138.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1464_CR57","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.vaccine.2008.01.007","volume":"26","author":"KJ Smith","year":"2008","unstructured":"Smith KJ, Zimmerman RK, Lin CJ, Nowalk MP, Ko F-S, McEllistrem MC, et\u00a0al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine. 2008;26(11):1420\u201331.","journal-title":"Vaccine"},{"key":"1464_CR58","doi-asserted-by":"crossref","unstructured":"Nagaraj G, Govindan V, Ganaie F, Venkatesha VT, Hawkins PA, Gladstone RA, et\u00a0al. Streptococcus pneumoniae genomic datasets from an Indian population describing pre-vaccine evolutionary epidemiology using a whole genome sequencing approach. Microb Genom. 2021;7(9).","DOI":"10.1099\/mgen.0.000645"},{"issue":"4","key":"1464_CR59","doi-asserted-by":"publisher","first-page":"e60273","DOI":"10.1371\/journal.pone.0060273","volume":"8","author":"MA Said","year":"2013","unstructured":"Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O\u2019Brien KL, Team AAPBS, et\u00a0al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE. 2013;8(4):e60273.","journal-title":"PLoS ONE"},{"key":"1464_CR60","unstructured":"Government of India. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY). https:\/\/www.india.gov.in\/spotlight\/ayushman-bharat-national-health-protection-mission. Accessed October 1 2023."},{"key":"1464_CR61","unstructured":"Government of India. Central Government Health Scheme (CGHS) Package Rate. 2021."},{"key":"1464_CR62","unstructured":"Implementation MoSaP. All India YoY Inflation for Year 2024\u201325. 2025. https:\/\/cpi.mospi.gov.in\/. Accessed 10 Sept 2026"},{"key":"1464_CR63","unstructured":"IndiaMart Export. Pneumococcal 13 Valent Conjugate Vaccine; Pneumococcal Polysaccharide Conjugate Vaccine. 2026. https:\/\/export.indiamart.com\/. Accessed September 10 2026."},{"issue":"7","key":"1464_CR64","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jval.2021.11.1370","volume":"25","author":"G Jyani","year":"2022","unstructured":"Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK, et\u00a0al. Development of an EQ-5D value set for India using an extended design (DEVINE) study: the Indian 5-level version EQ-5D value set. Value Health. 2022;25(7):1218\u201326.","journal-title":"Value Health"},{"issue":"1","key":"1464_CR65","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12879-017-2302-3","volume":"17","author":"MJ Mangen","year":"2017","unstructured":"Mangen MJ, Huijts SM, Bonten MJ, de Wit GA. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17(1):208.","journal-title":"BMC Infect Dis"},{"issue":"31-32","key":"1464_CR66","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","volume":"22","author":"A Melegaro","year":"2004","unstructured":"Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31\u201332):4203\u201314.","journal-title":"Vaccine"},{"key":"1464_CR67","unstructured":"fxtop. Historical Currency Converter by Date: Indian Rupee to US Dollar, on 31st December 2024. 2026. https:\/\/fxtop.com\/en\/historical-currency-converter.php?A=1&C1=INR&C2=USD&DD=31&MM=12&YYYY=2024&btnOK=Go%21&B=1&P=-2&I=1. Accessed July 15 2026."},{"key":"1464_CR68","unstructured":"WHO. Making choices in health: WHO guide to cost-effectiveness analysis. 2003. https:\/\/iris.who.int\/items\/45aadd1d-30c2-4cfa-a369-62a3b57592da. Accessed July 15 2026."},{"key":"1464_CR69","unstructured":"International Monetary Fund (IMF). GDP per capita, current prices. 2025. https:\/\/www.imf.org\/external\/datamapper\/NGDPDPC@WEO\/IND?zoom=IND&highlight=IND. Accessed 23 Jul 2025."},{"key":"1464_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040432","author":"P Kumar","year":"2025","unstructured":"Kumar P, Ray A, Kumari A, Sultana A, Hora R, Singh K, et\u00a0al. Chronicling the journey of pneumococcal conjugate vaccine introduction in India. Vaccines. 2025. https:\/\/doi.org\/10.3390\/vaccines13040432.","journal-title":"Vaccines"},{"key":"1464_CR71","unstructured":"Leidner AJ. Summary of three economic models assessing pneumococcal vaccines in US adults. Centers for Disease Control and Prevention (CDC); 2021 September 29."},{"key":"1464_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2025.101136","author":"J Zhang","year":"2025","unstructured":"Zhang J, Vietri J, Averin A, Hariharan D, Atwood M, Huang L. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years in Singapore. Value Health Reg Issues. 2025. https:\/\/doi.org\/10.1016\/j.vhri.2025.101136.","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"1464_CR73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12962-023-00458-4","volume":"21","author":"BM Malene","year":"2023","unstructured":"Malene BM, Oyvind H, Tor M, David NM, Jens O, Nanna VK, et\u00a0al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting. Cost Eff Resour Alloc. 2023;21(1):52.","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"1464_CR74","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1080\/13696998.2022.2152235","volume":"25","author":"J Olsen","year":"2022","unstructured":"Olsen J, Schnack H, Skovdal M, Vietri J, Mikkelsen MB, Poulsen PB. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23. J Med Econ. 2022;25(1):1240\u201354.","journal-title":"J Med Econ"},{"issue":"1","key":"1464_CR75","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1080\/14760584.2024.2350246","volume":"23","author":"S Nakamura","year":"2024","unstructured":"Nakamura S, Mikami M, Hayamizu T, Yonemoto N, Moyon C, Gouldson M, et\u00a0al. Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan. Expert Rev Vaccines. 2024;23(1):546\u201360.","journal-title":"Expert Rev Vaccines"},{"key":"1464_CR76","unstructured":"SCTIMST. Pneumococcal Conjugate Vaccine to prevent mortality and morbidity of pneumococcal disease in Indian Adults. Regional Technical Resource Centre for Health Technology Assessment, SCTIMST, Kerala & Health Technology Assessment in India (HTAIn). 2024."},{"issue":"Suppl 2","key":"1464_CR77","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.4103\/ijcm.ijcm_739_24","volume":"49","author":"CR Rao","year":"2024","unstructured":"Rao CR, Kamath VG, Nadda A, Parida SP, Sharma N, Goel K, et\u00a0al. IAPSM\u2019s position paper on pneumococcal vaccine (PCV) for adult immunization in India. Indian J Community Med. 2024;49(Suppl 2):S132\u20138.","journal-title":"Indian J Community Med"},{"issue":"4","key":"1464_CR78","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/21645515.2019.1682842","volume":"16","author":"R Dash","year":"2020","unstructured":"Dash R, Agrawal A, Nagvekar V, Lele J, Di Pasquale A, Kolhapure S, et\u00a0al. Towards adult vaccination in India: a narrative literature review. Hum Vaccin Immunother. 2020;16(4):991\u20131001.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1464_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15939-7","volume":"23","author":"A Janssens","year":"2023","unstructured":"Janssens A, Vaes B, Abels C, Cr\u00e8vecoeur J, Mamouris P, Merckx B, et\u00a0al. Pneumococcal vaccination coverage and adherence to recommended dosing schedules in adults: a repeated cross-sectional study of the INTEGO morbidity registry. BMC Public Health. 2023;23(1):1104.","journal-title":"BMC Public Health"},{"issue":"11","key":"1464_CR80","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.4103\/jfmpc.jfmpc_590_22","volume":"11","author":"S Sriram","year":"2022","unstructured":"Sriram S, Albadrani M. Impoverishing effects of out-of-pocket healthcare expenditures in India. J Fam Med Prim Care. 2022;11(11):7120\u20138.","journal-title":"J Fam Med Prim Care"},{"key":"1464_CR81","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1093\/ofid\/ofaa417.002","volume":"7","author":"B Essink","year":"2020","unstructured":"Essink B, Sabharwal C, Xu X, Sundaraiyer V, Peng Y, Moyer L, et\u00a0al. Phase 3 pivotal evaluation of 20-valent pneumococcal conjugate vaccine (PCV20) safety, tolerability, and immunologic noninferiority in participants 18 years and older. Open Forum Infect Dis. 2020;7:S2\u20135.","journal-title":"Open Forum Infect Dis"},{"key":"1464_CR82","unstructured":"Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP): Evidence to Recommendations for PCV20 use among adults 19\u201364 years old. 2024. https:\/\/www.cdc.gov\/acip\/evidence-to-recommendations\/pneumo-PCV20-risk-based-etr.html. Accessed July 28 2026."},{"issue":"8","key":"1464_CR83","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S1473-3099(26)00115-5","volume":"26","author":"AC Miles","year":"2026","unstructured":"Miles AC, Vojicic J, Peyrani P, Rosenstock S, Li H, Vietri JT, et\u00a0al. Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort study. Lancet Infect Dis. 2026;26(8):807\u201318.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"1464_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003326","volume":"17","author":"H Lawrence","year":"2020","unstructured":"Lawrence H, Pick H, Baskaran V, Daniel P, Rodrigo C, Ashton D, et\u00a0al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLoS Med. 2020;17(10):e1003326.","journal-title":"PLoS Med"},{"issue":"3","key":"1464_CR85","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1473-3099(17)30049-X","volume":"17","author":"M Suzuki","year":"2017","unstructured":"Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et\u00a0al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313\u201321.","journal-title":"Lancet Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01464-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01464-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01464-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:02:19Z","timestamp":1792440139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01464-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":85,"alternative-id":["1464"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01464-8","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Santosh Taur, Namrata Kulkarni, and Sachin Choudhari are employees and shareholders of Pfizer Ltd. India. Liping Huang is an employee and shareholder of Pfizer Inc. Ahuva Averin, Anu Suokas, Mary MacKinnon, and Mark Atwood are employees of Avalere Health, which received funding from Pfizer Inc. in connection with this study and the development of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted using publicly available data and previously conducted studies. It does not contain any new studies with human participants or animals performed by any of the authors, and hence no consent for publication was needed and the study was not subject to institutional review.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}